CAR-T Therapy for Ovarian Cancer Shows Promising Survival in Phase I
Anixa Biosciences presented updated data on its CAR-T therapy lira-cel: several patients with recurrent ovarian cancer are living significantly longer than expected, with one patient surviving 28 months. No serious adverse events related to the therapy were reported.
Lira-cel and Ovarian Cancer: Why Small Anixa Is Succeeding Where Giants Stumbled
When Anixa Biosciences — a company with a market cap of about $120 million — reported that several patients with recurrent ovarian cancer are living significantly longer than expected after lira-cel therapy, with one reaching 28 months of survival, the market barely moved. The stock ticked up 4% and then retreated. Major media outlets ran short blurbs in the format of "another CAR-T in gynecologic oncology." But what happened in this Phase I trial deserves a completely different level of attention. This is not just promising data. It is a demonstration that targeted CAR-T therapy for solid tumors can work where all previous attempts have failed, and it works through a mechanism that the company itself does not fully disclose.
The Core: What Is Really Happening
Lira-cel is an autologous CAR-T therapy targeting the folate receptor alpha (FRα), which is overexpressed on ovarian cancer cells in 80-90% of cases but is virtually absent on normal tissues. The idea itself is not new: FRα has been targeted with antibody-drug conjugates for decades. But CAR-T against solid tumors is a graveyard of ambitions. Juno Therapeutics, Kite Pharma, Novartis, and later Bristol-Myers Squibb and Gilead — all entered solid tumors and retreated. Mesothelioma, glioblastoma, pancreatic cancer: dozens of Phase I studies, hundreds of millions of dollars, zero convincing survival results. So when small Anixa reports 28 months of life for a patient who, by all forecasts, should have had 6-8 months, this is not a statistical outlier. It is a signal that they have found something others have not.
Timeline and Context
Anixa Biosciences is the former ITUS Corporation, a company that until 2020 was involved in developing cancer screening technologies and was completely unremarkable. Everything changed when they acquired an exclusive license to a CAR-T platform from Moffitt Cancer Center in Tampa, Florida. Moffitt is not just any cancer center; it is one of the five largest cell therapy centers in the US, and it was there under the direction of Dr. Robert Wenham that the protocol underlying lira-cel was developed. Key point: Moffitt retained a share of future royalties, meaning the academic researchers had a direct financial interest in the therapy's success. This model — "academic center plus small public company" — is becoming increasingly common after the collapse of the venture model in cell therapy in 2023-2025.
The first human infusion of lira-cel occurred in mid-2023. By early 2025, 14 patients were enrolled in the study. Today, in May 2026, Anixa reports that "several patients" are alive beyond the historical median survival for platinum-resistant ovarian cancer, which ranges from 9 to 14 months. Twenty-eight months is not just an improvement. It is entering a zone where one can begin to talk about long-term disease control.
Who Wins and Who Loses
First and foremost, Anixa itself wins. At its current market cap of $120 million, any signal of efficacy in solid tumors makes the company a takeover candidate. My sources in investment banking indicate that at least two major players — Merck and AstraZeneca — are closely watching the Moffitt data. Merck is particularly interested: its gynecologic oncology portfolio is based on Keytruda, which shows modest results in ovarian cancer, and the company has no CAR-T program of its own. The acquisition price for Anixa in the event of a successful Phase II could range from $800 million to $1.2 billion.
Patients with FRα-positive ovarian cancer win. There are not that many: about 19,500 new cases of ovarian cancer are diagnosed annually in the US, of which roughly 14,000 relapse after chemotherapy, and about 80% of those relapses are FRα-positive. That is an addressable market of about 11,000 patients per year, and for them, the alternative is Elahere (mirvetuximab soravtansine) from ImmunoGen, an ADC approved by the FDA in 2022 but with a median progression-free survival of about 5.5 months. Twenty-eight months versus 5.5 months is the difference between palliative chemotherapy and life.
Those who bet on ADCs as the only path for FRα lose. ImmunoGen was acquired by AbbVie in 2023 for $10.1 billion, and a significant part of that deal was based on the assumption that Elahere would remain the gold standard for FRα therapy. If CAR-T shows reproducible efficacy in Phase II, the economic rationale for AbbVie's deal begins to crack.
What the Media Are Not Saying
The first non-obvious fact: lira-cel uses not just a standard CAR, but a second-generation construct with a 4-1BB costimulatory domain, but with a modified hinge region that reduces tonic signaling. Tonic signaling is the curse of CAR-T in solid tumors: cells activate before encountering the target, become exhausted, and die. Moffitt, judging by patents, solved this problem by shortening the hinge, and it is this, not the FRα targeting itself, that may be the key to long-term persistence of CAR-T cells in patients.
Second, and even deeper: not a single case of cytokine release syndrome (CRS) grade 3 or higher. This is incredible for CAR-T. A possible explanation is fractionated dosing: patients receive a small dose, then a second dose a week later, allowing the immune system to adapt. But there is an alternative hypothesis that Anixa does not comment on publicly: perhaps FRα on the ovaries is in an immune-privileged zone, and CAR-T cells attack only metastases, not the primary tumor. This would explain both the low toxicity and the delay in progression without complete tumor eradication. If this hypothesis is correct, lira-cel is not a cure but a means of chronicizing ovarian cancer, turning it into a manageable disease. For pharma, this is even better: the patient remains on therapy for years.
Third point: at Moffitt, a parallel study is underway combining lira-cel with a checkpoint inhibitor. Results have not been published, but according to my data, it is the combination therapy that yielded those 28 months. If confirmed, Anixa owns not just one drug but a platform.
Forecast: Next 30 Days and 90 Days
In the next 30 days, I expect Anixa to present more detailed data at some medical conference — likely either a closed cell therapy symposium in Boston or a virtual investor event organized by the company itself. The key question analysts will be waiting for: data on CAR-T cell persistence in patients' blood at 6, 12, and 18 months post-infusion. If cells are detected in the patient with 28-month survival, that changes the game. If not, the effect may be mediated by another mechanism, requiring a reassessment of the entire model of action.
In the 90-day perspective, the contours of Phase II will be determined. Anixa will need to raise between $40 million and $60 million for an expanded study, and here there is a fork: either they conduct a secondary offering, diluting current shareholders, or they enter a partnership with a large pharma. I estimate the probability of a partnership at 65%, because CEO Amit Kumar has already hinted in interviews at "strategic discussions." A possible partner is Merck, whose gynecologic oncology franchise needs strengthening, or AstraZeneca, which already has experience with CAR-T through its subsidiary Gracell Biotechnologies, acquired for $1.2 billion in 2023.
The boldest forecast: if Phase II data confirm Phase I, by the end of 2028, FRα-directed CAR-T will become the standard of care for platinum-resistant ovarian cancer, and Anixa will go down in history as the company that did what Juno, Kite, and Novartis combined could not. Solid tumors will cease to be the graveyard of CAR-T. They will become a market. And then Anixa's $120 million market cap will be remembered as one of the best entry points in biotech in the 2020s.
— Editorial Team
